Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $85.25 Average PT from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given an average rating of “Moderate Buy” by the four analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $85.25.

A number of analysts recently weighed in on the stock. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, StockNews.com cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th.

Prestige Consumer Healthcare Stock Down 1.5 %

NYSE:PBH opened at $82.30 on Monday. The firm has a market capitalization of $4.07 billion, a PE ratio of 20.02, a price-to-earnings-growth ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare has a 52 week low of $57.95 and a 52 week high of $86.36. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a 50 day moving average of $78.12 and a 200-day moving average of $72.54.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm’s revenue was down .9% on a year-over-year basis. During the same period in the prior year, the business earned $1.07 EPS. Analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the transaction, the senior vice president now owns 18,835 shares in the company, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last quarter. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of PBH. OLD National Bancorp IN purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter valued at $262,000. QRG Capital Management Inc. lifted its stake in Prestige Consumer Healthcare by 4.7% during the second quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock valued at $372,000 after buying an additional 242 shares in the last quarter. ORG Partners LLC acquired a new position in shares of Prestige Consumer Healthcare in the second quarter worth about $39,000. Robbins Farley increased its position in shares of Prestige Consumer Healthcare by 7.7% in the second quarter. Robbins Farley now owns 31,480 shares of the company’s stock worth $2,167,000 after acquiring an additional 2,240 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Prestige Consumer Healthcare by 106.9% during the second quarter. Blue Trust Inc. now owns 867 shares of the company’s stock valued at $63,000 after acquiring an additional 448 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.